Molecularly imprinted nanoparticles as drug carriers to the brain.

Autor: Figueiredo, Eduardo Costa, Seabra, Catarina Leal, Mendes, Tássia Venga, Rosa, Mariana Azevedo, Pinho, Cláudia Daniela Lacerda Nunes, de Oliveira Figueiredo, Daniela Mayra, Boralli, Vanessa Bergamin, Junior, Milton Kennedy Aquino, de Lima, Maria Eduarda Tavares, Reis, Salette
Předmět:
Zdroj: Journal of Materials Science; Dec2023, Vol. 58 Issue 46, p17578-17593, 16p
Abstrakt: Molecularly imprinted polymers (MIPs) have a high potential for use as drug delivery carriers. These materials exhibit beneficial properties such as stability, low toxicity, biodegradability, and the ability to form specific binding sites. New systems capable of crossing the blood–brain barrier (BBB) are important for the development of new treatments for nervous central system diseases. Due to the presence of apolipoprotein E (ApoE) receptors in the BBB, some nanomaterials functionalized with ApoE may be efficient systems for the drug delivery in the brain. In this way, a nano-MIP conjugated with ApoE (MIP-ApoE) was synthesized, characterized and evaluated as a possible drug nanocarrier to the brain. A non-imprinted polymer (NIPs) and a NIP conjugated with ApoE (NIP-ApoE) were also synthesized and compared with MIP and MIP-ApoE. The nanoparticles were loaded with donepezil (drug used for a proof-of-principle study), and the formulations were tested for cytocompatibility, in vitro release, and permeability through BBB model using hCMEC/D3 cells. Free donepezil, donepezil-loaded nanoparticles, and unloaded nanoparticles had a hemolytic activity lower than 15% and cell viability greater than 70%. The quantified donepezil in the plasma samples of animals treated with MIP and MIP-ApoE supported the in vitro results of sustainable donepezil release by these nanoparticles. When the nanoparticles were functionalized with ApoE, the permeability in the hCMEC/D3 monolayer increased (1.9 times). The brain samples of animals treated with MIP-ApoE had a slightly lower concentration of donepezil than the MIP treatment. One possible explanation is that, only the MIP-ApoE, with part of the donepezil complexed at its binding sites, can penetrate the brain. As a result, a reduced amount of donepezil remains free to be quantified. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje